Kelderman Kim 4

What Happened Kim Kelderman, a director of ConMed Corporation (CNMD), received a grant of 5,772 restricted stock units (RSUs) on June 1, 2026. The Form 4 reports the acquisition as a derivative award at $0.00 per unit (common for RSU grants), so there was no cash purchase. These RSUs represent a contingent right to receive one share of common stock per RSU once vesting conditions are met.

Key Details

• Transaction date: 2026-06-01; Form 4 filed 2026-06-03 (timely filing).
• Grant: 5,772 RSUs reported as an award/derivative at $0.00.
• Shares owned after transaction: not specified in this filing.
• Footnote: RSUs are subject to the Company’s 2025 Long-Term Incentive Plan and generally vest 100% after one year.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag indicated in the filing.

Context RSU grants are a common form of executive/director compensation and are different from open-market purchases or sales—these are future contingent rights to shares that typically vest over time. Because the filing lists RSUs at $0, the reported dollar value here is not the market value; eventual value depends on ConMed’s share price at vesting and any applicable tax-withholding arrangements. This award signals alignment of the director’s compensation with shareholder value but is not itself a buy/sell signal.